Complete response of secukinumab in palmoplantar psoriasis

Rocamora, Vicenç; Garcías-Ladaria, Joan

doi:10.5070/d32310037014

Cited by 5 publications

(4 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, the urgency of its treatment should be taken into consideration. Unfortunately, palmoplantar psoriasis is also frequently resistant to treatment, making it quite a therapeutic challenge [2]. Biologic therapies, such as secukinumab, an anti-interleukin (IL) 17A monoclonal antibody, have been highly effective in the management of resistant palmoplantar psoriasis, as shown in the 2PRECISE randomized controlled trial [3] and GESTURE trial [4].…”

Section: Introductionmentioning

confidence: 99%

Palmoplantar Psoriasis Successfully Treated With Risankizumab

Alajlan¹,

Qadoumi²

2021

Cureus

View full text Add to dashboard Cite

Palmoplantar psoriasis is a variant of psoriasis that affects the palms and soles. Despite the small body surface area affected, palmoplantar psoriasis can have significant implications on a patient’s mental health, justifying the urgency in treating this condition. Palmoplantar psoriasis is also known to be challenging to treat. In this case report, we present a male who presented with a 15-year history of psoriasis with significant palmoplantar involvement, managed with topical and systemic therapies, achieving a minimal response. After trying other therapies including acitretin and adalimumab, we eventually started the patient on risankizumab, an anti-IL-23 antibody. Following the fourth dose of risankizumab, the patient’s palmoplantar lesions completely resolved. We further discuss why risankizumab may be considered a treatment option in resistant palmoplantar psoriasis cases.

show abstract

Section: Introductionmentioning

confidence: 99%

Palmoplantar Psoriasis Successfully Treated With Risankizumab

Alajlan¹,

Qadoumi²

2021

Cureus

View full text Add to dashboard Cite

show abstract

“…A recent meta-analysis of 43 real-life studies has concluded on the effectiveness of this biologic for moderate-to-severe psoriasis and pointed out the elevated drug retention rates, favorable tolerability profile, and improved patient reported outcomes [29]. Real-life evidence about the use of secukinumab for the treatment of palmoplantar psoriasis, on the other hand, is very limited [30][31][32]. A recent real-life study in 83 psoriasis patients, 25.3% of whom had palmoplantar psoriasis confirmed the effectiveness and high retention rates of secukinumab and found that patients naïve to biologics and without coexisting psoriatic arthritis had the greatest benefits [32].…”

Section: Discussionmentioning

confidence: 99%

Secukinumab for the treatment of palmoplantar psoriasis: a 2-year, multicenter, real-life observational study

Galluzzo

Talamonti

Atzori

et al. 2022

Expert Opinion on Biological Therapy

View full text Add to dashboard Cite

Background: Palmoplantar psoriasis is difficult to treat and often recalcitrant to conventional therapies. Clinical trials have demonstrated the efficacy and safety of secukinumab for this debilitating psoriasis form, but real-life evidence is currently limited. Therefore, here we described the outcomes of patients treated with secukinumab in clinical practice. Research Design and Methods: This was a real-life, retrospective, observational study involving patients with palmoplantar psoriasis treated with secukinumab (300 mg, subcutaneously) at seven dermatologic clinics in Italy. Treatment effectiveness was evaluated based on the changes of the Psoriasis Area and Severity Index (PASI) and palmoplantar (pp) PASI during treatment and by recording safety and tolerability issues over 104 weeks. Results: Forty-three patients initiated treatment with secukinumab. Previous treatments included topical and systemic therapies; half of patients had already tried one or more biologics. Secukinumab improved mean PASI rapidly and substantially with a 78.2% decrease at 16 weeks. Mean ppPASI also improved substantially, but more gradually, with reductions of 55.0% and 79.3% at 16 and 104 weeks, respectively. Approximately half of patients achieved complete skin clearance at 40 weeks. Secukinumab was well tolerated and no relevant treatment-related adverse events were reported. Conclusions: Secukinumab appears to be effective for the treatment of palmoplantar psoriasis also in the real-life setting.

show abstract

“…Data on the specific treatment of PP are scarce because patients with PP are often excluded from clinical trials due to the limited BSA (<10%). In addition, this variant of psoriasis is often resistant to treatments, making its clinical management a challenge for physicians 7 …”

Section: Introductionmentioning

confidence: 99%

“…In addition, this variant of psoriasis is often resistant to treatments, making its clinical management a challenge for physicians. 7 According to a systematic review, 8 biologics can be effective in both hyperkeratotic PP and pustular PP. 9 Noteworthy, guselkumab, an anti-IL-23A monoclonal antibody, was recently approved in Japan for the treatment of pustular PP in patients refractory to previous conventional treatments, after an RCT showed its safety and efficacy at 16 weeks, that was maintained up to 52 weeks.…”

Section: Introductionmentioning

confidence: 99%

Drug survival of biologics and non‐biologics in patients affected by palmoplantar psoriasis: a “real‐world”, mono‐center experience

Caldarola,

Falco,

Calabrese

et al. 2023

Int J Dermatology

View full text Add to dashboard Cite

BackgroundData on the treatment of palmoplantar psoriasis (PP) are very limited as these patients are often excluded from clinical trials. Moreover, this form of psoriasis is often resistant to treatment, making its clinical management complex.MethodsPrimary endpoint was to evaluate the clinical and demographic characteristics and the drug survival of both biological and non‐biological drugs in a population affected by PP. Secondary endpoint was to highlight any differences between the hyperkeratotic and pustular variant. We analyzed data from 233 psoriasis patients with palmoplantar involvement, with or without chronic plaque psoriasis. We performed a drug‐survival analysis with the aid of Kaplan‐Meier survival and a multivariate analysis to highlight the influence of certain variables on treatment persistence using a Cox regression model.ResultsThe drug‐survival analysis revealed that biologic drugs compared to non‐biologic drugs are associated with a higher persistence in treatment (59.73 vs. 43.56%); in particular, anti‐IL23 drugs were found to be the drugs with the best drug‐survival overall (67.94% of patients at 60 months are still on these drugs). Furthermore, our multivariate analysis shows that when compared with biological drugs, non‐biological drugs are associated with an increased risk of treatment discontinuation (HR = 1.95 [95% CI: 1.41–2.68], P = 0.001).ConclusionsOur study confirms the difficulty of treating PP and shows that biologic drugs are associated with longer persistence in treatment than non‐biologics in both PP's variants, not because of their higher effectiveness but because of their better safety profile.

show abstract

Complete response of secukinumab in palmoplantar psoriasis

Cited by 5 publications

References 5 publications

Palmoplantar Psoriasis Successfully Treated With Risankizumab

Palmoplantar Psoriasis Successfully Treated With Risankizumab

Secukinumab for the treatment of palmoplantar psoriasis: a 2-year, multicenter, real-life observational study

Drug survival of biologics and non‐biologics in patients affected by palmoplantar psoriasis: a “real‐world”, mono‐center experience

Contact Info

Product

Resources

About